{"entity":{"id":"nct06389006","kind":"trial","name":"To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer","aka":[],"tldr":"A phase 2 trial of Disitamab vedotin, Toripalimab, Epirubicin and Cyclophosphamide in HER2-positive breast cancer and HR-positive / HER2-negative breast cancer, run by RemeGen Co., Ltd., now recruiting.","summary":"To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer is a phase 2 interventional study registered as NCT06389006 by RemeGen Co., Ltd., with 79 participants planned, started 2024-04-29 and due to reach its primary completion in 2025-06-01. Interventions recorded: Disitamab Vedotin for Injection, Toripalimab, Epirubicin and Cyclophosphamide.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06389006","url":"https://clinicaltrials.gov/study/NCT06389006"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-her2-positive","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["disitamab-vedotin","toripalimab","epirubicin","cyclophosphamide"],"companies":["remegen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06389006","phase":"2","setting":"A Single-arm, Open-label, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer","sponsor":"RemeGen Co., Ltd.","enrolled":79,"outcomes":[]},"route":"/trials/nct06389006/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"drug":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"disitamab-vedotin","kind":"drug","name":"Disitamab vedotin","route":"/drugs/disitamab-vedotin/"},{"id":"epirubicin","kind":"drug","name":"Epirubicin","route":"/drugs/epirubicin/"},{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"company":[{"id":"remegen","kind":"company","name":"RemeGen","route":"/companies/remegen/"}]}}